SIGNIFOR LAR 20 MG
PASIREOTIDE (PASIREOTIDE PAMOATE) : 20 MG · DIN 02437252 · RECORDATI RARE DISEASES CANADA INC
Health Canada status: MARKETED
What is SIGNIFOR LAR?
SIGNIFOR LAR 20 MG contains PASIREOTIDE (PASIREOTIDE PAMOATE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02437252, held by RECORDATI RARE DISEASES CANADA INC, supplied as POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT for INTRAMUSCULAR administration. Health Canada currently lists it as marketed, status dated 21-May-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SIGNIFOR LAR used for?
Treatment of adults with acromegaly or Cushing’s disease for whom surgery is not an option or has failed. 60 mg dose is for acromegaly only.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02437252 |
|---|---|
| Brand name | SIGNIFOR LAR |
| Generic / active ingredient | PASIREOTIDE (PASIREOTIDE PAMOATE) : 20 MG |
| Manufacturer | RECORDATI RARE DISEASES CANADA INC |
| Strength | 20 MG |
| Dosage form | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT |
| Route of administration | INTRAMUSCULAR |
| Schedule | Prescription |
| ATC code | H01CB05 PASIREOTIDE |
| AHFS class | 68:29.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-May-2020 |
| Original market date | 2016-01-28 00:00:00 |
How is it administered?
Acromegaly: Initial 40 mg IM every 4 weeks; max 60 mg. Cushing’s: Initial 10 mg IM every 4 weeks; max 40 mg. Administered by deep intramuscular injection by a healthcare professional.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Refrigerated storage (2-8°C). Do not freeze. Kit must reach room temperature (min 30 mins) before reconstitution.
How is it supplied?
Kits containing one single-use vial of powder (10, 20, 30, 40, or 60 mg), one 2 mL prefilled syringe of diluent, one vial adapter, and one safety needle.
Contraindications
Moderate/severe hepatic impairment; uncontrolled diabetes (HbA1c ≥8%); NYHA Class III-IV heart failure; severe bradycardia; QT interval ≥500 ms; hypersensitivity to pasireotide.
Warnings and precautions
Risk of hepatotoxicity (Hy’s Law reported), cardiovascular events (QT prolongation, bradycardia), and severe hyperglycemia/diabetes. Monitor glucose, LFTs, and ECG.
What can be used instead?
Other Canadian products sharing ATC code H01CB05 PASIREOTIDE. 8 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SIGNIFOR | 0.3 MG | SOLUTION | RECORDATI RARE DISEASES CANADA INC | MARKETED | DIN 02413299 |
| SIGNIFOR | 0.6 MG | SOLUTION | RECORDATI RARE DISEASES CANADA INC | MARKETED | DIN 02413302 |
| SIGNIFOR | 0.9 MG | SOLUTION | RECORDATI RARE DISEASES CANADA INC | MARKETED | DIN 02413310 |
| SIGNIFOR LAR | 10 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | DIN 02480425 |
| SIGNIFOR LAR | 30 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | DIN 02480433 |
| SIGNIFOR LAR | 40 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | DIN 02437260 |
| SIGNIFOR LAR | 60 MG | POWDER FOR SUSPENSION, SUSTAINED-RELEASE ; KIT | RECORDATI RARE DISEASES CANADA INC | MARKETED | DIN 02437279 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.